	US 11,897,866 B2
	Heteroaryl inhibitors of PAD4
Rajesh Devraj, Chesterfield, MO (US); Gnanasambandam Kumaravel, Lexington, MA (US); Holly Atton, Abingdon (GB); Edward Beaumont, Abingdon (GB); Elise Gadouleau, Abingdon (GB); Laura Gleave, Abingdon (GB); Philip Stephen Kerry, Abingdon (GB); Cristina Lecci, Abingdon (GB); Mirco Meniconi, Abingdon (GB); Nat Monck, Abingdon (GB); Jordan Palfrey, Abingdon (GB); Kostas Papadopoulos, Abingdon (GB); Heather Tye, Abingdon (GB); and Philip A. Woods, Abingdon (GB)
Assigned to Padlock Therapeutics, Inc., Princeton, NJ (US)
Filed by Padlock Therapeutics, Inc., Princeton, NJ (US)
Filed on Nov. 9, 2021, as Appl. No. 17/522,348.
Application 17/522,348 is a division of application No. 16/078,376, granted, now 11,198,681, previously published as PCT/US2017/018790, filed on Feb. 22, 2017.
Claims priority of provisional application 62/298,726, filed on Feb. 23, 2016.
Prior Publication US 2022/0081418 A1, Mar. 17, 2022
Int. Cl. C07D 401/14 (2006.01); A61K 31/437 (2006.01); A61K 31/4184 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01)

CPC C07D 401/14 (2013.01) [A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01)]

15 Claims

15. The method according to claim 14, wherein said subject is a human subject.